NCT06602193 - Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

February 28, 2028

Conditions

Parkinson Disease

Interventions

DRUG

BIIB122 225 mg

Administered as specified in the treatment arm

OTHER

BIIB122-Matching Placebo

Administered as specified in the treatment arm

Trial Locations (16)

10003

RECRUITING

Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center, New York

33486

RECRUITING

Parkinson's Disease and Movement Disorders Center, Boca Raton

90048

RECRUITING

Cedars-Sinai Department of Neurology, Los Angeles

94158

RECRUITING

University of California San Francisco, San Francisco

98034

RECRUITING

Evergreen Health Laboratory, Kirkland

99202

RECRUITING

Inland Northwest Research, Spokane

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

Unknown

RECRUITING

Technische Universität Dresden, Dresden

RECRUITING

University of Lübeck, Lübeck

RECRUITING

University Hospital Tübingen, Tübingen

RECRUITING

Hospital Universitari General de Catalunya, Barcelona

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

RECRUITING

Hospital Universitario Donostia, Donostia / San Sebastian

RECRUITING

Universitary Hospital La Princesa, Madrid

RECRUITING

IDIVAL/University Hospital Marques de Valdecilla, Santander

RECRUITING

Hospital Universitario Virgen del Rocio, Seville